Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605378 · ClinicalTrials.gov registry record
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
A clinical trial of Chronic Granulomatous Disease (CGD), sponsored by Ensoma.
- Recruiting
- Registry status
- 60
- Enrollment target
- 20
- Study locations
NCT06605378 is a study of Chronic Granulomatous Disease (CGD) that is actively recruiting participants, run by Ensoma. The registered enrollment target is 60 participants. The trial reports 20 study locations across 19 states.
The verdict
NCT06605378, a study of Chronic Granulomatous Disease (CGD), is actively recruiting participants, sponsored by Ensoma.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Conditions Studied
Study Locations (20)
California
- Home-based telemedicine - Sacramento
- University of California, San Francisco - San Francisco
Alabama
- Home-based telemedicine - Montgomery
Arizona
- Home-based telemedicine - Phoenix
Arkansas
- Home-based telemedicine - Little Rock
Colorado
- Home-based telemedicine - Denver
Connecticut
- Home-based telemedicine - Hartford
Delaware
- Home-based telemedicine - Dover
District of Columbia
- Home-based telemedicine - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06605378
The ClinicalTrials.gov registry entry for NCT06605378 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensoma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Granulomatous Disease (CGD) appearing as the primary indexed condition, and to 0 interventions.
NCT06605378 reports 20 study locations spanning 19 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06605378 about?
NCT06605378 is a clinical study titled "Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease". This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
What is the current status of trial NCT06605378?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2024-11-18. Estimated completion is 2026-06.
What conditions does trial NCT06605378 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease (CGD).
Who is sponsoring clinical trial NCT06605378?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605378 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease (CGD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.